Plain-English translation of NCT04392206 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
Researchers are testing whether Allogeneic (AMSC) can improve the success of arteriovenous fistulas — the surgically created connections between arteries and veins that allow people on kidney dialysis to receive treatment more effectively. The stem cells would be applied during the fistula creation surgery to reduce the risk of the connection narrowing or closing over time. This is an early-stage study (Phase 1) focused on safety and how well this treatment works.
Many people with end-stage kidney disease need dialysis, which requires a reliable access point in the blood vessels. Unfortunately, these surgical connections often narrow or fail, requiring repeat surgeries and causing problems with treatment. This medication may help prevent that narrowing and keep the access working longer.
You likely qualify if…
You likely don't qualify if…
If you qualify, you would undergo your scheduled fistula creation surgery with the addition of the stem cell treatment applied during the procedure. The study would then monitor you over time to check that the access is healing well, the connection stays open, and there are no safety concerns. You would need to be able to attend follow-up visits and communicate with the research team about how you're doing.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
United States
Phase
Safety & dosing
Sponsor
Houssam Farres, M.D.
Enrollment target
~15 participants
Started
May 2020
Primary completion
June 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 85 Years
Last updated on clinicaltrials.gov in August 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Reagan Dukes
Mayo Clinic
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.